On March 15, 2023 Akeso Inc. (HKEX Code: 9926.HK, "Akeso", or the "Company") reported its 2022 annual report (Press release, Akeso Biopharma, MAR 15, 2023, View Source [SID1234628836]). During the reporting period, the company enjoyed booming business development and made breakthrough progress in drug innovation and development, commercialization and internationalization.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

开坦尼（cadonilimab, PD-1/CTLA-4 bispecific antibody）saw a strong start

With excellent safety and efficacy profile, a well-established commercialization platform and great efforts by the highly productive sales force, 开坦尼 recorded strong sales of RMB546.3 million for the financial year ended December 31, 2022.

On June 29, 2022, 开坦尼 , the first-in-class PD-1/CTLA-4 bi-specific antibody independently developed by the company, has been granted marketing approval by the NMPA for the treatment of recurrent or metastatic cervical cancer (R/M CC) patients who have progressed on or after platinum-based chemotherapy. 开坦尼 is the first approved dual immune checkpoint inhibitor bispecific antibody globally, addressing a huge unmet medical need for immunotherapy for advanced cervical cancer in China, and is also pioneering the development of bispecific antibodies in China.

安尼可(penpulimab injection, PD-1), jointly developed by Akeso and Sino Biopharmaceutical Limited (stock code: 1177.HK), recorded product sales of RMB558.1 million in 2022, increasing 164%. In April 2022, three indications were included in the 2022 CSCO Guideline, which are penpulimab for treatment of refractory/relapsed classic Hodgkin Lymphoma (r/r cHL), penpulimab in combination with chemotherapy as first-line treatment of squamous NSCLC, penpulimab as secondline treatment or salvage treatment of recurrent/metastatic nasopharyngeal carcinoma (r/m NPC). In January 2023, 安尼可 in combination with chemotherapy as first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer was approved by NMPA.

Expediting global collaboration and development signified by landmark outlicensing transaction of ivonescimab (PD-1/VEGF, AK112）

Another breakthrough development was overseas licensing which set a new record for the transaction amount of a single innovative drug in China. In December 2022, exclusive development licensing rights were granted to Summit Therapeutics in the United States, Canada, Europe and Japan for ivonescimab, a breakthrough PD-1/VEGF bispecific antibody independently developed by Akeso. Akeso has received an upfront payment equivalent to US$500 million and the total potential deal value is up to US$5 billion, including regulatory and commercial milestone payments. Akeso will also receive a low double-digit percentage of royalties on net product sales.

Currently, the cooperation between the two sides has been deeply and completely carried out, which fully demonstrates the huge global commercialization potential of ivonescimab and paves a fast track for its globalization and commercialization.

Strong R&D efficiency contributed to six products in 14 Pivotal/Phase III studies

During the reporting period, Akeso’s new drug development entered the advanced stage in batches, and a total of 14 clinical studies were in the Pivotal/Phase III stage, six of which have completed enrollment and will soon submit marketing applications.

The Phase III clinical studies on 开坦尼 for major indications including first-line cervical cancer, first-line gastric cancer and hepatocellular cancer were advanced efficiently, while those for first-line cervical cancer and first-line gastric cancer were enrolled.

The patient enrollment of Phase III clinical trial of ivonescimab plus chemotherapy versus chemotherapy in EGFR mutated advanced non-squamous NSCLC that failed in prior EGFR-TKI therapy, has been completed. Ivonescimab monotherapy versus pembrolizumab monotherapy as the first-line treatment for NSCLC patients with positive PD-L1 expression is going well, and the Phase III trial of ivonescimab plus chemotherapy versus PD-1 inhibitor plus chemotherapy for advanced squamous NSCLC was approved. Ivonescimab has received Breakthrough Therapy Designation Status in China for three indications in lung cancer.

In the field of autoimmunity and metabolism, the first applications for new drug marketing are expected to be submitted in 2023 for two Phase III studies on ebdarokimab (IL-12/IL-23, AK101) for the treatment of moderate to severe psoriasis and ebronucimab (PCSK9, AK102) for the treatment of hypercholesterolemia.

"We are pleased to see our best performance since the company’s establishment, particularly the strong growth in sales of our two new drugs, as well as the record licensing agreements for our self-developed drug, which reflect the tremendous clinical and commercial value of our innovative drugs and demonstrate our robust commercialization capability in the first place. These achievements are mainly due to our strategic vision and R&D layout ability, its drug innovation R&D system at the forefront of science, a high standard and demanding production system, and our professional management and execution. These provide a solid foundation for us to fulfill our mission and embark on a new journey in biopharma," said Dr. Michelle Xia, co-founder, Chairwoman, CEO, and President of Akeso.

"Over the next five years, we will be launching more than six independently developed new drug varieties, covering a broad range of areas including cancer, autoimmunity and metabolism." Dr. Michelle Xia said.

On March 15, 2023 MorphoSys AG (FSE: MOR; NASDAQ: MOR) reported results for the fourth quarter and the full year 2022 (Press release, MorphoSys, MAR 15, 2023, View Source/en/news/morphosys-ag-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides" target="_blank" title="View Source/en/news/morphosys-ag-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides" rel="nofollow">View Source [SID1234628835]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"2022 was a defining year for MorphoSys. We made advances in our pipeline by progressing our Phase 3 clinical trials, including pelabresib in myelofibrosis and tafasitamab in lymphomas. We also out-licensed highly promising, early and mid-stage product candidates, enabling us to concentrate exclusively on our work in oncology," said Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys. "In 2023, we will continue to prioritize the Phase 3 study of pelabresib in myelofibrosis, on our way to sharing topline data in early 2024 and exploring its potential use in other myeloid diseases. We remain steadfast in our commitment to developing and delivering novel therapies that are safer and more effective for cancer patients, and we look forward to the future."

Pelabresib Highlights:

On January 9, 2023, MorphoSys announced that topline data from the ongoing Phase 3 MANIFEST-2 study are expected to be available in early 2024.

MorphoSys presented at ASH (Free ASH Whitepaper) 2022 results from analyses of the ongoing MANIFEST study in patients with myelofibrosis. The latest analyses include longer-term data showing durable improvements in both spleen volume and symptom score beyond 24 weeks, with pelabresib plus ruxolitinib in JAK inhibitor-naïve patients.

Monjuvi/Minjuvi Highlights:

Monjuvi (tafasitamab-cxix) U.S. net product sales of US$ 25.3 million (€ 24.7 million) for the fourth quarter 2022 (Q4 2021: US$ 23.6 million (€ 20.5 million)) and US$ 89.4 million (€ 84.9 million) for the full year of 2022 (2021: US$ 79.1 million (€ 66.9 million)).

Minjuvi royalty revenue of € 0.7 million for sales outside of the U.S. in the fourth quarter 2022 and € 3.0 million for the full year of 2022.

Tafasitamab Data:

At the ASH (Free ASH Whitepaper) conference in December 2022, final safety and efficacy results from firstMIND, a Phase 1b, open-label, randomized safety study combining tafasitamab or tafasitamab plus lenalidomide with standard R-CHOP were presented, showing no new safety signals and providing additional information on progression-free survival at 24 months for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) treated with tafasitamab plus lenalidomide and R-CHOP. Two additional analyses also suggested that sensitive assays to detect minimal residual disease have prognostic value at the end of first-line therapy.

Corporate Developments:

On December 6, 2022, MorphoSys’ fully owned subsidiary Constellation Pharmaceuticals, Inc. entered into a global licensing agreement with Novartis to research, develop, and commercialize its preclinical inhibitors of a novel cancer target. Under the terms of the agreement, Novartis will assume full responsibility for all subsequent research, development, and commercialization activities for the program. As part of the agreement, MorphoSys received an immediate upfront payment of US$ 23 million. On achievement of development, regulatory, and commercial milestones, MorphoSys will be eligible to receive milestone payments from Novartis in addition to mid-single to low-double-digit royalties on program net sales.

On December 20, 2022, MorphoSys announced that Sung Lee, the company’s Chief Financial Officer and Management Board member, has decided to leave MorphoSys to move back to California. His last day with MorphoSys will be March 17, 2023.

Significant Events After the End of the Fourth Quarter of 2022:

On March 2, 2023, MorphoSys announced that it will stop work and operations on its pre-clinical research programs to optimize its cost structure. MorphoSys will reduce its workforce at the company’s headquarters in Planegg, Germany, by approximately 17%. This action, along with other steps taken over the past year, enables MorphoSys to focus resources on its mid- to late-stage oncology pipeline.

On March 14, 2023, MorphoSys announced that Lucinda Crabtree, Ph.D., will join as Chief Financial Officer and member of the Management Board. She will start in the third quarter 2023 at the latest.

Charlotte Lohmann was appointed as Chief Legal Officer on March 1, 2023 and will serve as a member of MorphoSys’ Management Board ad interim.

Financial Results for the Fourth Quarter of 2022 (IFRS):

Total revenues for the fourth quarter 2022 were € 81.6 million compared to € 52.9 million for the same period in 2021. This increase resulted mainly from higher revenues from the global licensing agreement with Novartis executed in the fourth quarter 2022.

in € million* Q4 2022 Q3 2022 Q4 2021 Q-Q Δ Y-Y Δ

Total revenues 81.6 95.8 52.9 (15) % 54 %
Monjuvi product sales 24.7 21.9 20.5 13 % 20 %
Royalties 29.1 29.7 23.2 (2) % 25 %
Licenses, milestones and other 27.9 44.1 9.3 (37) % > 100%
* Differences due to rounding.
Cost of Sales: In the fourth quarter of 2022, cost of sales was € 15.4 million compared to € 9.5 million for the same period in 2021. The fourth quarter of 2022 includes € 5.1 million of expenses related to activities to optimize the Monjuvi supply chain.

Research and Development (R&D) Expenses: In the fourth quarter 2022, R&D expenses were € 94.0 million compared to € 87.0 million for the same period in 2021. The increase is primarily due to clinical trial material expenses in the fourth quarter 2022 partially offset by lower personnel costs.

Selling, General and Administrative (SG&A) Expenses: Selling expenses in the fourth quarter 2022 were € 23.0 million compared to € 32.5 million for the same period in 2021. The decrease was driven by higher investments in 2021 made into the commercial organization, the first full year after the Monjuvi launch. General and administrative (G&A) expenses amounted to € 17.5 million compared to € 18.2 million for the same period in 2021.

Operating Loss: Operating loss amounted to € 68.4 million in the fourth quarter 2022 compared to a loss of € 325.0 million for the same period in 2021. The lower year-over-year operating loss was primarily driven by the impairment of goodwill amounting to € 230.7 million recognized in the fourth quarter 2021.

Consolidated Net Profit / Loss: For the fourth quarter 2022, consolidated net profit was € 329.4 million compared to a net loss of € 381.0 million for the same period in 2021. The consolidated net profit in the fourth quarter 2022 was driven mainly by the recognition of finance income triggered by the reduction in financial liabilities from collaborations.

Financial Results for the Full Year 2022 (IFRS):

Total Revenues for the full year 2022 were € 278.3 million compared to € 179.6 million in 2021. The increase resulted mainly from higher revenues from licenses due to the out-licensing agreements with HI-Bio and Novartis. Royalties in 2022 include € 3.0 million from the sale of Minjuvi outside of the U.S. by our partner Incyte and € 96.9 million from Tremfya sales which is fully passed on to Royalty Pharma.

in € million* 2022 2021 Y-Y Δ

Total revenues 278.3 179.6 55 %
Monjuvi product sales 84.9 66.9 27 %
Royalties 99.9 65.6 52 %
Licenses, milestones and other 93.5 47.2 98 %
* Differences due to rounding.
Cost of Sales: For the full year 2022, cost of sales were € 48.6 million compared to € 32.2 million in 2021. The increase was primarily driven by higher sales of Monjuvi in the U.S. and Minjuvi outside of the U.S. and expenses related to activities to optimize the Monjuvi supply chain.

R&D Expenses: For the full year 2022, R&D expenses were € 297.8 million compared to € 225.2 million in 2021. The R&D expenses increased primarily due to higher development activity and the inclusion of expenses from the Constellation acquisition since Q3 2021.

SG&A Expenses: Selling expenses for the full year 2022 were € 92.4 million compared to € 121.5 million in 2021. The decrease was primarily driven by higher investments made into the commercial organization in 2021, the first full year after the Monjuvi launch. G&A expenses amounted to € 60.1 million for 2022 compared to € 78.3 million in 2021. The decrease was driven primarily by the transaction costs related to the Constellation and Royalty Pharma agreements in 2021.

Operating Loss: Operating loss amounted to € 220.7 million for the full year 2022 compared to a loss of € 508.3 million in 2021. The lower year-over-year operating loss was primarily driven by the impairment of goodwill amounting to € 230.7 million recognized in 2021.

Consolidated Net Loss: For the full year 2022, consolidated net loss was € 151.1 million compared to a net loss of € 514.5 million in 2021. The lower consolidated net loss in 2022 was driven mainly by the recognition of finance income triggered by the reduction in financial liabilities from collaborations.

Cash and Other Financial Assets: As of December 31, 2022, the Company had cash and other financial assets of € 907.2 million compared to € 976.9 million on December 31, 2021.

Number of shares: The number of shares issued totaled 34,231,943 on December 31, 2022, no change compared to December 31, 2021.

Full Year 2023 Financial Guidance:

Amounts in million 2023 Financial Guidance 2023 Guidance Insights
Monjuvi U.S. net product sales US$ 80m to 95m 100% of Monjuvi U.S. net product sales are recorded on MorphoSys’ income statement and related profit/loss is split 50/50 between MorphoSys and Incyte.
Gross margin for Monjuvi U.S. net product sales 75% to 80% 100% of Monjuvi U.S. product cost of sales are recorded on MorphoSys’ income statement and related profit/loss is split 50/50 between MorphoSys and Incyte.
R&D expenses € 290m to 315m 2023 anticipated to be incrementally higher than 2022 due to the expansion of the pelabresib development program.
SG&A expenses € 140m to 155m 45% to 50% of mid-point of SG&A expenses represent Monjuvi U.S. selling costs of which 100% are recorded in MorphoSys’ income statement. Incyte reimburses MorphoSys for half of these selling expenses.
Additional information related to 2023 Financial Guidance:

Tremfya royalties will continue to be recorded as revenue without any cost of sales in MorphoSys’ income statement. These royalties, however, will not contribute any cash to MorphoSys, as 100% of the royalties will be passed on to Royalty Pharma.
MorphoSys anticipates receiving royalties for Minjuvi sales outside of the U.S.
MorphoSys does not anticipate any significant cash-accretive revenues from the achievement of milestones in 2023.
MorphoSys anticipates sales of commercial and clinical supply of tafasitamab outside of the U.S. to its partner Incyte. Revenue from this supply is recorded in the "Licenses, milestones and other" category in MorphoSys’ income statement. These sales result in a zero gross profit/margin. As such, MorphoSys does not provide guidance for these sales
Operational Outlook:

The following events and development activities planned for 2023 and beyond include the following:

full patient enrollment for the pivotal Phase 3 study (MANIFEST-2) of pelabresib in myelofibrosis (MF) in 2023 with topline results anticipated in early 2024;
primary analysis data from the Phase 3 study (inMIND) of tafasitamab in patients with indolent lymphoma (r/r FL/MZL) in 2024;
primary analysis data from the pivotal Phase 3 study (frontMIND) of tafasitamab in previously untreated DLBCL in the second half of 2025.
MorphoSys Group Key Figures (IFRS, end of financial year: December 31, 2022)

in € million Q4 2022 Q4 2021 Δ 2022 2021 Δ
Revenues 81.6 52.9 54 % 278.3 179.6 55 %
Product Sales 24.7 20.5 20 % 84.9 66.9 27 %
Royalties 29.1 23.2 25 % 99.9 65.6 52 %
Licenses, Milestones and Other 27.9 9.3 >100% 93.5 47.2 98 %
Cost of Sales (15.4) (9.5) 62 % (48.6) (32.2) 51 %
Gross Profit 66.2 43.4 53 % 229.6 147.4 56 %
Total Operating Expenses (134.6) (368.4) (63) % (450.4) (655.8) (31) %
Research and Development (94.0) (87.0) 8 % (297.8) (225.2) 32 %
Selling (23.0) (32.5) (29) % (92.4) (121.5) (24) %
General and Administrative (17.5) (18.2) (4) % (60.1) (78.3) (23) %
Impairment of Goodwill — (230.7) (100) % — (230.7) (100) %
Operating Profit / (Loss) (68.4) (325.0) (79) % (220.7) (508.3) (57) %
Other Income (7.8) 3.4 >(100)% 12.0 8.2 46 %
Other Expenses 7.4 (1.7) >(100)% (15.6) (6.4) >100%
Finance Income 325.0 (2.7) >(100)% 412.1 96.6 >100%
Finance Expenses 249.5 (89.0) >(100)% (165.9) (181.5) (9) %
Income from Reversals of Impairment Losses / (Impairment Losses) on Financial Assets 0.4 (0.2) >(100)% — 0.3 (100) %
Share of Loss of Associates accounted for using the Equity Method (4.0) — n/a (4.3) — n/a
Income Tax Benefit / (Expenses) (172.7) 34.4 >(100)% (168.6) 76.6 >(100)%
Consolidated Net Profit / (Loss) 329.4 (381.0) >(100)% (151.1) (514.5) (71) %
Earnings per Share, Basic and Diluted (in €) — (11.16) n/a (4.42) (15.40) (71) %
Earnings per Share, Basic 9.64 — n/a — — n/a
Earnings per Share, Diluted 8.93 — n/a — — n/a
Cash and other financial assets (end of period) 907.2 976.9 * (7) % 907.2 976.9 * (7) %

* Value as of December 31, 2021

MorphoSys will hold its conference call and webcast tomorrow, March 16, 2023, at 1:00pm CET (12:00pm GMT/8:00am EDT) to present the results for the fourth quarter and the full year 2022.

Participants for the conference call and webcast may pre-register and will receive dedicated dial-in details to easily and quickly access the call:

View Source;linkSecurityString=469447192

Please dial in 10 minutes before the beginning of the conference.

A live webcast and slides will be made available at the Investors section under "Events & Conferences" on MorphoSys’ website, View Source and after the call, a slide-synchronized audio replay of the conference will be available at the same location.

Consolidated Financial Statements 2022 (IFRS) are available for download at:

View Source/en/investors/financial-information

On March 15, 2023 Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, reported its financial results and provide a corporate update for the fiscal year ended December 31, 2022 on Wednesday, March 29, 2023 (Press release, MediGene, MAR 15, 2023, View Source [SID1234628834]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Following the release of the full year 2022 financial results on Medigene’s website, the company will host a conference call that same day at 3 p.m. CET (9 a.m. ET).

Full details for the conference call and webcast are as follows:

Date March 29, 2023
Time 3:00 p.m. CET (9 a.m. ET)
U.S. Dial-in Number: +1 877-451-6152
Int’l Dial-in Number: +1 201-389-0879
Conference ID: 13736670
Webcast: Join the live webcast here or at View Source
Please dial in 10 minutes ahead of time to ensure a timely start of the conference call.

Following the call, an archived webcast will be accessible on the Investors & Media section of the Medigene website: View Source

On March 15, 2023 Onconova Therapeutics, Inc. (NASDAQ: ONTX), ("Onconova"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, reported the publication of two abstracts that have been accepted for poster presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, which is taking place at the Orange County Convention Center in Orlando, Florida from April 14 – 19, 2023 (Press release, Onconova Therapeutics, MAR 15, 2023, View Source [SID1234628833]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The full texts of the published abstracts can be found on the AACR (Free AACR Whitepaper) Annual Meeting website. The corresponding posters will be presented during the "Cyclin-dependent Kinases and Cyclin-dependent Kinase Inhibitors" poster session, which is taking place from 9:00 a.m. – 12:30 p.m. ET on April 19, 2023. Additional information on the posters is shown below.

Poster Title: Synergistic activity of the CDK4/6 antagonist narazaciclib (ON123300) with irreversible BTK inhibition in ibrutinib-resistant mantle cell lymphoma

Abstract Number: 5974

This poster will describe studies evaluating narazaciclib in preclinical models of mantle cell lymphoma (MCL). Results from these studies demonstrated narazaciclib’s single-agent antitumor activity in MCL cell lines independent of their sensitivity to ibrutinib, which is a Bruton’s tyrosine kinase inhibitor (BTKi) approved by the U.S. Food and Drug Administration (FDA) for the treatment of MCL. When combining narazaciclib with ibrutinib, synergistic increases in antitumor activity against both BTKi-resistant and BTKi-sensitive MCL cell lines were observed.

Additional analyses showed that narazaciclib’s antitumor activity against the evaluated MCL cell lines was superior to that of the FDA-approved CDK 4/6 inhibitors palbociclib and ribociclib, and similar to that of the FDA-approved CDK 4/6 inhibitor abemaciclib. Treatment with narazaciclib also led to tumor growth inhibition without detectable toxicity in a chicken embryo chorioallantoic membrane (CAM) xenograft model of MCL.

Poster Title: Differential targets engaged by narazaciclib in comparison to the approved CDK4/6 inhibitors contribute to enhanced inhibition of tumor cell growth

Abstract Number: 5987

This poster will describe cell-based, in vitro, and bioinformatic analyses comparing narazaciclib and palbociclib. Results from a cell-based murine mammary carcinoma model showed a stronger induction of programmed cell death with narazaciclib compared to palbociclib. In vitro and cell-based analyses revealed multiple targets that are engaged by narazaciclib but not by palbociclib. These targets included BUB1, the overexpression of which is correlated with poor survival in triple negative breast cancer. The results of additional cell-based assays that will be described in the poster suggest that narazaciclib may promote antitumor immunity and show that combining narazaciclib with autophagy inhibitors sensitizes breast cancer cells to cell death.

On March 15, 2023 Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today that it will host a conference call and webcast to provide a business and clinical update on Tuesday, March 21, 2023 at 4:30 p.m. EDT (Press release, Cue Biopharma, MAR 15, 2023, View Source [SID1234628832]). Live and archived versions of the event can be accessed via the Company’s website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Members of the Cue Biopharma executive management team will provide a clinical update from the Company’s ongoing trials evaluating its lead interleukin 2 (IL-2)-based biologic, CUE-101, as a monotherapy and in combination with pembrolizumab (KEYTRUDA) for patients with recurrent/metastatic HPV+ head and neck cancer. Management will also provide updates on CUE-102, the Company’s second IL-2-based clinical drug candidate for the treatment of Wilms’ Tumor 1 (WT1) expressing cancers, its strategic objectives and anticipated milestones including Cue Biopharma’s most recent partnership with Ono Pharmaceutical to advance the Company’s lead autoimmune disease asset, CUE-401, toward the clinic.

Webcast Details

Tuesday, March 21 at 4:30 p.m. EDT

Investors: 1-877-407-9208
International: 1-201-493-6784
Conference ID: 13736864
Request a return call via the Call me link: View Source;passcode=13736864&h=true&info=company-email&r=true&B=6
Participants can use the guest dial-in numbers above and be answered by an operator or click the Call me link for instant telephone access. The link will be active 15 minutes prior to the scheduled start time.
Webcast: View Source;tp_key=6f69873566